Dynavax Presents Encouraging Data From Clinical Trial of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Dynavax Presents Encouraging Data From Clinical Trial of Immuno-Oncology Product Candidate, SD-101

BERKELEY, CA --(Marketwired - April 18, 2016) - Dynavax Technologies Corporation ( NASDAQ : DVAX ) today announced encouraging additional data from Part 1 of a Phase 1/2 study (LYM-01) evaluating the company's lead immunotherapy product candidate, SD-101, in combination with low-dose radiation in lymphoma patients. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisiana.

Clinical Findings Included:

  • SD-101 was reported to be well tolerated across all dose cohorts with no dose limiting toxicities.
  • The combination of direct injection of SD-101 into a tumor and low-dose radiation resulted in changes in the tumor microenvironment that potentially induced a systemic anti-tumor response.
  • Tumors not directly injected with SD-101 also decreased in volume across all dose groups, and in most patients, remained stable for at least 180 to 360 days.
  • No evidence of a dose response was observed, although limited numbers of patients were examined.

"This clinical trial design is unique and takes advantage of the fact that lymphoma patients have easily injectable sites of disease. The local injections are conveniently added to low dose radiotherapy, a standard treatment for low grade lymphoma," stated Ronald Levy, M.D., professor and chief of the Division of Oncology at Stanford School of Medicine and the study's lead clinical investigator. "We are pleased to have already demonstrated a safety profile, pharmacodynamics and preliminary efficacy in this study," he said.

"These additional data bolster the findings that were presented at the American Society of Hematology conference in December, demonstrating SD-101's ability to promote beneficial changes in the tumor microenvironment to induce a systemic antitumor immune response," stated Eddie Gray, chief executive officer for Dynavax.

Two additional presentations relating to SD-101 are being made at the AACR Conference -- abstract 2322 this afternoon and abstract 4985 on Wednesday morning. Both presentations contain preclinical data relating to SD-101, and all three data presentations will be available on Dynavax's website ( www.dynavax.com ) at the "Events and Presentations" tab under the "Investors and Media" section of the website.

About LYM-01, a Phase 1/2 Trial of SD-101 in Lymphoma

In the Phase 1/2 non-randomized, open-label, multicenter, dose-escalation and expansion study, patients had untreated low-grade B-cell lymphoma. At least two sites of measurable disease were required for participation -- one of which was treated with low dose radiation and was then injected with SD-101 on days 1, 8, 15, 22 and 29. Other lesions received no treatment.

In Part 1-- the dose escalation portion of the study -- four dose cohorts with three patients each, received SD-101 at either 1 mg, 2 mg, 4 mg, or 8 mg. The Phase 2 expansion portion of the study is ongoing and is currently enrolling two dose cohorts. The primary endpoints of the trial are maximum tolerated dose (MTD) and evaluation of the safety of intratumoral SD-101 in combination with low dose radiotherapy. In addition, the trial is evaluating anti-tumor activity, pharmacodynamics, and duration of response. For more information about trial enrollment, please look for SD-101 at www.clinicaltrials.gov .

About SD-101

SD-101, the subject of AACR abstracts CT047, 2322 and 4985, is Dynavax's proprietary, second-generation, CpG-C class oligodeoxynucleotide TLR 9 agonist. SD-101 activates multiple anti-tumor mechanisms of innate immune cells and activates plasmacytoid dendritic cells to stimulate T cells specific for antigens released from dying tumor cells. TLR9 agonists such as SD-101 enhance T and B cell responses and induce high levels of Type I interferons and maturation of plasmacytoid dendritic cells and B cells. SD-101 is being evaluated in several Phase 1/2 oncology studies to assess its preliminary safety and activity. 

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B™, a Phase 3 investigational adult hepatitis B vaccine and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information, visit  www.dynavax.com .

Forward-Looking Statements

This press release contains forward-looking statements regarding clinical studies involving SD-101, Dynavax's investigational cancer immunotherapy. These statements are subject to a number of risks and uncertainties that could cause actual results to differ materially, including enrollment and completion of clinical trials; the results of clinical trials and the impact of those results on the initiation or continuation of subsequent trials; issues arising in the regulatory process; and other risks detailed in the "Risk Factors" section of our most recent current periodic report filed with the SEC. These statements represent our estimates and assumptions only as of the date of this press release. We do not undertake any obligation to update publicly any such forward-looking statements, even if new information becomes available. Information on Dynavax's website at www.dynavax.com is not incorporated by reference in our current periodic reports with the SEC.

Contact: Michael Ostrach Chief Financial Officer 510-665-7257 Email contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 53

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 141

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 144

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 163

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 107

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 82

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
TIER IV Simplifies Autonomous Driving with CARLA 1.0

Updated Category News Views 38

No More Detours in Autonomous Development Ever messed with a puzzle that just won't fit until suddenly, it clicks? That's what TIER IV just pulled off with their latest work on CARLA 1.0, the open-source simulator. There's no more mucking about with that separate Python-based bridge to get things communicating—now we're talking native Autoware support. A direct line to...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 91

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionary Prostate Treatment Program Launches in Dallas

Updated Category News Views 191

Transforming Prostate Care with the TULSA Program The landscape of prostate treatment is evolving, thanks to the groundbreaking advancements brought forth by Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) and its launch of the TULSA program in collaboration with Texas Prostate and Dallas Medical Center. This pioneering initiative aims to cater to the rising need for...

Continue Reading
Addex Expands Share Capital for Future Financial Flexibility

Updated Category News Views 254

Recent Developments at Addex Therapeutics Ad Hoc Announcement Addex Therapeutics, a clinical-stage biopharmaceutical firm, has made a significant move by issuing 34,300,000 new registered shares. These shares, issued by Addex Pharma S.A, a wholly-owned subsidiary, allow the company to strategically increase its issued share capital to CHF 2,186,544.96. This adjustment...

Continue Reading
Jasper Therapeutics Receives Major Boost from Oppenheimer's $80 Target

Updated Category News Views 130

Oppenheimer Affirms Positive Outlook for Jasper Therapeutics Jasper Therapeutics (NASDAQ:JSPR) has recently captured the attention of investors, particularly following Oppenheimer's announcement of its continued support with an Outperform rating and a notable price target set at $80. The positive sentiment originates from the recent findings of a Phase 1b/2a clinical...

Continue Reading
Taylor Morrison Launches New Resort Community Near Jacksonville

Updated Category News Views 286

Taylor Morrison Launches New Resort Community Near Jacksonville In an exciting development for homebuyers, Taylor Morrison, recognized as one of America’s Most Trusted® Home Builders, has officially broken ground on its first resort lifestyle community in the Jacksonville area. This ambitious project, named Esplanade at St. Marys, spans an impressive 1,250 acres and is...

Continue Reading
Middlefield Canadian Income PCC Report: NAV Insights

Updated Category News Views 123

Understanding Middlefield Canadian Income PCC's Financial Position Middlefield Canadian Income PCC is a notable player in the investment landscape, focusing on generating sustainable income from a diversified portfolio. Understanding its net asset value (NAV) is crucial for investors looking to gauge the company's financial stability and growth potential. Current Net...

Continue Reading